MENOPUR MULTIDOSE 1200 IU

Quốc gia: Israel

Ngôn ngữ: Tiếng Anh

Nguồn: Ministry of Health

Thành phần hoạt chất:

MENOTROPHIN

Sẵn có từ:

FERRING PHARMACEUTICALS LTD

Mã ATC:

G03GA02

Dạng dược phẩm:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Thành phần:

MENOTROPHIN 1200 IU

Tuyến hành chính:

S.C, I.M

Loại thuốc theo toa:

Required

Sản xuất bởi:

FERRING GmbH ,GERMANY

Nhóm trị liệu:

HUMAN MENOPAUSAL GONADOTROPHIN

Khu trị liệu:

HUMAN MENOPAUSAL GONADOTROPHIN

Chỉ dẫn điều trị:

Sterility in females with hypo or normogonadotropic ovarian insufficiency: stimulation of follicle growth. Sterility in males with hypo or normogonadotropic hypogonadism: In combination with HCG to spermatogenesis

Ngày ủy quyền:

2017-02-28

Tờ rơi thông tin

[לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט *
[סגירה]
סגור *
דף הבית [http://www.health.gov.il/] *
אודות *
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx] *
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx] *
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx] *
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx] *
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx] *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3] *
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx] *
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx] *
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx] *
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx] *
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx] *
יחידות המשרד *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx] *
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx] *
נושאים *
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx] *
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/

Đặc tính sản phẩm

1.
NAME OF THE MEDICINAL PRODUCT
MENOPUR multidose 600 IU
MENOPUR multidose 1200 IU
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
MENOPUR 600 IU: Each vial of powder contains highly purified
menotrophin (human
menopausal gonadotrophin, HMG) corresponding to 600 IU human follicle
stimulating
hormone (FSH) and 600 IU human luteinizing hormone (LH) activity.
MENOPUR 1200 IU: Each vial of powder contains highly purified
menotrophin (human
menopausal gonadotrophin, HMG) corresponding to 1200 IU follicle
stimulating hormone
(FSH) and 1200 IU human luteinizing hormone (LH) activity.
Human Chorionic Gonadotrophin (hCG), a naturally occurring hormone
in postmenopausal urine, is present in MENOPUR and contributes to the
overall luteinizing
hormone activity. Menotrophin is produced from human urine.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder and solvent for solution for injection.
Appearance of powder: white to off-white lyophilised cake.
Appearance of solvent: clear colourless solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the treatment of Sterility in females with hypo or
normogonadotropic ovarian
insufficiency: stimulation of follicle growth.
Sterility in males with hypo or normogonadotropic hypogonadism: In
combination with HCG
to spermatogenesis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment with MENOPUR should be initiated under the supervision of a
physician
experienced in the treatment of fertility problems.
METHOD OF ADMINISTRATION
MENOPUR is intended for subcutaneous (S.C.) or intramuscular (I.M.)
injection after
reconstitution with the solvent provided. The powder should be
reconstituted prior to use. The
reconstituted solution is for multiple injections and can be used for
up to 28 days. Vigorous
shaking should be avoided. The solution should not be used if it
contains particles or if it is
not clear.
DOSAGE
Dosage regimens described below are identical for S.C. and I.M.
administration.
There are great inter-individual variations in the response of the
ov